UPDATE 1-FDA staff question utility of Sanofi diabetes drugs
May 23, 2016 at 09:45 AM EDT
May 23 (Reuters) - A preliminary review by the U.S. Food and Drug Administration questioned whether Sanofi SA's experimental diabetes drug lixisenatide contributed any benefit to a fixed-dose combination product the company hopes to market.